TY - JOUR
T1 - Axitinib-related osteonecrosis of the jaw
AU - Patel, Vinod
AU - Sproat, Chris
AU - Kwok, Jerry
AU - Tanna, Nikki
PY - 2017/8/18
Y1 - 2017/8/18
N2 - Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw.
AB - Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw.
UR - http://www.scopus.com/inward/record.url?scp=85029416450&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2017.08.003
DO - 10.1016/j.oooo.2017.08.003
M3 - Article
AN - SCOPUS:85029416450
SN - 2212-4403
JO - Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics
JF - Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics
ER -